会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • SIMULTANEOUS ASSAY FOR DETERMINING DRUGS
    • 同时测定药物的同时测定
    • US20090053733A1
    • 2009-02-26
    • US12187661
    • 2008-08-07
    • William F. LinkRenato B. del RosarioRandy V. SweetDavid L. King
    • William F. LinkRenato B. del RosarioRandy V. SweetDavid L. King
    • G01N33/53G01N33/566
    • G01N33/54326G01N33/94G01N2446/00Y10T436/101666Y10T436/108331Y10T436/25125
    • A method and kits for assaying a sample of a human or mammalian bodily fluid to simultaneously determine whether one or more of a plurality of drugs and/or metabolites thereof are present in said sample and optionally to perform a semi-quantitative assay for said drug or drugs, comprising: (a) incubating the sample in a competitive assay with a plurality of drug conjugates and a plurality of primary antibodies that bind to the drugs whose presence and optionally whose amount is to be determined, wherein either the plurality of drugs or the plurality of primary antibodies is coupled to microparticles comprising magnetically responsive material, the particles being divided into subsets of particles, each distinguishable from the others by one or more differentiation parameters and by the drug to which they are coupled; (b) incubating the product of step (a) with a liquid medium comprising one or more labeled ligands for the primary antibodies or drug conjugates; (c) magnetically separating microparticles in all of said groups from said liquid medium; and defining said liquid medium as a first liquid medium; (d) resuspending said microparticles separated therefrom in a second liquid medium; and (e) analyzing said microparticles in said second liquid medium by flow cytometry and identifying drugs present in the sample, and optionally calculating a semi-quantitative result for drugs found to be present.
    • 一种用于测定人或哺乳动物体液的样品以同时确定所述样品中是否存在多种药物和/或其代谢物中的一种或多种的方法和试剂盒,并任选地对所述药物进行半定量测定, 药物,其包括:(a)在竞争性测定中用多种药物偶联物和多种一级抗体孵育所述样品,所述多种药物结合物与其存在和任选地其量待确定的药物结合,其中所述多种药物或 多个第一抗体偶联到包含磁响应材料的微粒上,颗粒被分成颗粒子集,每个颗粒可以通过一个或多个分化参数和它们所联接的药物与其它子区别; (b)将步骤(a)的产物与包含一种或多种用于一抗或药物偶联物的标记配体的液体培养基进行培养; (c)将所有组中的微粒与所述液体介质磁分离; 并将所述液体介质限定为第一液体介质; (d)将其中分离的所述微粒重新悬浮在第二液体介质中; 和(e)通过流式细胞术分析所述第二液体培养基中的所述微粒并鉴定样品中存在的药物,并且可选地计算发现存在的药物的半定量结果。
    • 2. 发明授权
    • Simultaneous assay for determining drugs
    • 用于确定药物的同时测定
    • US07947465B2
    • 2011-05-24
    • US12187661
    • 2008-08-07
    • William F. LinkRenato B. del RosarioRandy V. SweetDavid L. King
    • William F. LinkRenato B. del RosarioRandy V. SweetDavid L. King
    • G01N33/00
    • G01N33/54326G01N33/94G01N2446/00Y10T436/101666Y10T436/108331Y10T436/25125
    • Bodily fluid is analyzed for the presence of drugs of a selected panel of drugs in a simultaneous assay in which sample of the fluid is incubated with additional amounts of all drugs of the panel, antibodies specific to each of the drugs of the panel, and microparticles, the microparticles being divided into subsets, one subset for each drug in the panel and each subset distinguishable from the others. The incubation is performed in a liquid medium in which competitive binding occurs, the drugs in the sample competing with those added to the assay medium for binding to the antibodies. In one procedure, the added drugs are pre-coupled to the microparticles while the antibodies are not, and the incubation is followed by further incubating the microparticles with labeled ligands that have affinity for the antibodies. In an alternative procedure, the added drugs are not coupled to the microparticles but are pre-labeled, while the antibodies are pre-coupled to the microparticles, and the assay proceeds without further incubation. In both alternatives, the microparticles are ultimately recovered from the assay medium and from any unbound species, and the recovered microparticles are analyzed by flow cytometry to obtain indications of the presence of the various drugs in the sample in an inverse manner by detection of the label, each drug differentiable from the others by the distinguishing features of the microparticles.
    • 在同时测定中分析体液中所选择的药物组的药物的存在,其中将流体样品与附加量的所有药物,面板每种药物特异的抗体和微粒 ,将微粒分为子集,面板中每种药物的一个子集,以及与其他子集可区分的每个子集。 孵育在其中发生竞争性结合的液体培养基中进行,样品中的药物与添加到测定培养基中的药物与抗体结合。 在一个程序中,将所添加的药物预先偶联到微粒,而不是抗体,然后孵育后,用对抗体具有亲和性的标记配体进一步孵育微粒。 在替代方法中,所添加的药物不与微粒偶联,而是预先标记,而抗体预偶联于微粒,并且测定在不进一步孵育的情况下进行。 在两种替代方案中,微粒最终从测定培养基和任何未结合物质中回收,并且通过流式细胞术分析回收的微粒,以通过检测标签以相反的方式获得样品中各种药物的存在的迹象 ,每种药物通过微粒的区别特征与其他药物不同。
    • 3. 发明申请
    • SIMULTANEOUS ASSAY FOR DETERMINING DRUGS
    • 同时测定药物的同时测定
    • US20110190169A1
    • 2011-08-04
    • US13086229
    • 2011-04-13
    • William F. LinkRenato B. del RosarioRandy V. SweetDavid L. King
    • William F. LinkRenato B. del RosarioRandy V. SweetDavid L. King
    • C40B40/10
    • G01N33/54326G01N33/94G01N2446/00Y10T436/101666Y10T436/108331Y10T436/25125
    • Bodily fluid is analyzed for the presence of drugs of a selected panel of drugs in a simultaneous assay in which sample of the fluid is incubated with additional amounts of all drugs of the panel, antibodies specific to each of the drugs of the panel, and microparticles, the microparticles being divided into subsets, one subset for each drug in the panel and each subset distinguishable from the others. The incubation is performed in a liquid medium in which competitive binding occurs, the drugs in the sample competing with those added to the assay medium for binding to the antibodies. In one procedure, the added drugs are pre-coupled to the microparticles while the antibodies are not, and the incubation is followed by further incubating the microparticles with labeled ligands that have affinity for the antibodies. In an alternative procedure, the added drugs are not coupled to the microparticles but are pre-labeled, while the antibodies are pre-coupled to the microparticles, and the assay proceeds without further incubation. In both alternatives, the microparticles are ultimately recovered from the assay medium and from any unbound species, and the recovered microparticles are analyzed by flow cytometry to obtain indications of the presence of the various drugs in the sample in an inverse manner by detection of the label, each drug differentiable from the others by the distinguishing features of the microparticles.
    • 在同时测定中分析体液中所选择的药物组的药物的存在,其中将流体样品与附加量的所有药物,面板每种药物特异的抗体和微粒 ,将微粒分为子集,面板中每种药物的一个子集,以及与其他子集可区分的每个子集。 孵育在其中发生竞争性结合的液体培养基中进行,样品中的药物与添加到测定培养基中的药物与抗体结合。 在一个程序中,将所添加的药物预先偶联到微粒,而不是抗体,然后孵育后,用对抗体具有亲和性的标记配体进一步孵育微粒。 在替代方法中,所添加的药物不与微粒偶联,而是预先标记,而抗体预偶联于微粒,并且测定在不进一步孵育的情况下进行。 在两种替代方案中,微粒最终从测定培养基和任何未结合物质中回收,并且通过流式细胞术分析回收的微粒,以通过检测标签以相反的方式获得样品中各种药物的存在的迹象 ,每种药物通过微粒的区别特征与其他药物不同。
    • 4. 发明授权
    • Simultaneous assay for determining drugs
    • 用于确定药物的同时测定
    • US08137987B2
    • 2012-03-20
    • US13086229
    • 2011-04-13
    • William F. LinkRenato B. del RosarioRandy V. SweetDavid L. King
    • William F. LinkRenato B. del RosarioRandy V. SweetDavid L. King
    • G01N33/52G01N33/543
    • G01N33/54326G01N33/94G01N2446/00Y10T436/101666Y10T436/108331Y10T436/25125
    • Bodily fluid is analyzed for the presence of drugs of a selected panel of drugs in a simultaneous assay in which sample of the fluid is incubated with additional amounts of all drugs of the panel, antibodies specific to each of the drugs of the panel, and microparticles, the microparticles being divided into subsets, one subset for each drug in the panel and each subset distinguishable from the others. The incubation is performed in a liquid medium in which competitive binding occurs, the drugs in the sample competing with those added to the assay medium for binding to the antibodies. In one procedure, the added drugs are pre-coupled to the microparticles while the antibodies are not, and the incubation is followed by further incubating the microparticles with labeled ligands that have affinity for the antibodies. In an alternative procedure, the added drugs are not coupled to the microparticles but are pre-labeled, while the antibodies are pre-coupled to the microparticles, and the assay proceeds without further incubation. In both alternatives, the microparticles are ultimately recovered from the assay medium and from any unbound species, and the recovered microparticles are analyzed by flow cytometry to obtain indications of the presence of the various drugs in the sample in an inverse manner by detection of the label, each drug differentiable from the others by the distinguishing features of the microparticles.
    • 在同时测定中分析体液中所选择的药物组的药物的存在,其中将流体样品与附加量的所有药物,面板每种药物特异的抗体和微粒 ,将微粒分为子集,面板中每种药物的一个子集,以及与其他子集可区分的每个子集。 孵育在其中发生竞争性结合的液体培养基中进行,样品中的药物与添加到测定培养基中的药物与抗体结合。 在一个程序中,将所添加的药物预先偶联到微粒,而不是抗体,然后孵育后,用对抗体具有亲和性的标记配体进一步孵育微粒。 在替代方法中,所添加的药物不与微粒偶联,而是预先标记,而抗体预偶联于微粒,并且测定在不进一步孵育的情况下进行。 在两种替代方案中,微粒最终从测定培养基和任何未结合物质中回收,并且通过流式细胞术分析回收的微粒,以通过检测标签以相反的方式获得样品中各种药物的存在的迹象 ,每种药物通过微粒的区别特征与其他药物不同。